Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia

Autor:	Tedeschi, A, Picardi, P, Ferrero, S, Benevolo, G, Margiotta, Casaluci, G, Varettoni, M, Baratè, C, Motta, M, Gini, G, Goldaniga, Mc, Visco, C, Zaja, Francesco, Belsito Petrizi, V, Ravelli, E, Gentile, M, Urbano, Ma, Franceschetti, S, Ghione, P, Orsucci, L, Frustaci, Am, Gaidano, G, Vitolo, U, Morra, E.
Přispěvatelé:	Tedeschi, A, Picardi, P, Ferrero, S, Benevolo, G, Margiotta Casaluci, G, Varettoni, M, Baratè, C, Motta, M, Gini, G, Goldaniga, Mc, Visco, C, Zaja, Francesco, Belsito Petrizi, V, Ravelli, E, Gentile, M, Urbano, Ma, Franceschetti, S, Ghione, P, Orsucci, L, Frustaci, Am, Gaidano, G, Vitolo, U, Morra, E.
Rok vydání:	2015
Předmět:	Bendamustine Male medicine.medical_specialty Cancer Research Salvage therapy Aggressive lymphoma Neutropenia Gastroenterology rituximab salvage Recurrence Internal medicine Antineoplastic Combined Chemotherapy Protocols 80 and over Medicine Bendamustine Hydrochloride Humans Aged Retrospective Studies Waldenström macroglobulinemia Aged 80 and over Salvage Therapy business.industry Secondary Myelodysplastic Syndrome refractory relapsed Female Follow-Up Studies Middle Aged Retreatment Rituximab Treatment Outcome Waldenstrom Macroglobulinemia Hematology Oncology Waldenstrom macroglobulinemia medicine.disease Surgery business Diffuse large B-cell lymphoma medicine.drug
Zdroj:	Leukemialymphoma. 56(9)
ISSN:	1029-2403
Popis:	According to the European Society for Medical Oncology and National Comprehensive Cancer Network guidelines on Waldenström macroglobulinemia, bendamustine (B) may be considered a suitable therapeutic option. To address the role of B in combination with rituximab (BR), we analyzed the outcome of 71 patients with relapsed/refractory disease, median age 72 years, treated with R 375 mg/m(2) day 1 and B days 1 and 2 (dosage ranging from 50 to 90 mg/m(2)). Patients had previously received a median number of 2 lines of treatment (range 1-5). Overall and major response rates were 80.2% and 74.6%. Major toxicity was grade 3/4 neutropenia occurring in 13% of courses. There was no significant association between baseline features or patients' characteristics and response achievement. Median progression-free survival was not reached after a median follow-up of 19 months (range 3-54). None of the patients developed aggressive lymphoma or secondary myelodysplastic syndrome/acute myeloid leukemia. BR was found to be an active and well-tolerated salvage regimen leading to rapid disease control.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b64103a182ff184005681415544bc2c https://pubmed.ncbi.nlm.nih.gov/26054374 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.